Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on August 13, 2026. The filing serves to announce the issuance of a press release containing unaudited financial results for the quarter ended June 30, 2026.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text provided for analysis.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the announcement of quarterly results without providing comparative data or variance analysis in the body of the 8-K.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, or unusual items are not detailed in this filing. The document explicitly states that the information regarding results is contained in the attached press release and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for actual revenue, net income, and cash flow figures.
- Verify the unaudited nature of the financial results for the quarter ended June 30, 2026.
- Check for any forward-looking statements or risk factors disclosed in the attached press release rather than this 8-K summary.
- Confirm the trading status of Common Stock (Symbol: ICCC) on The NASDAQ Capital Market.